Dalamax Mechanism of Action

Pharmacotherapeutic Group: Anti-bacterial.
Pharmacology: Pharmacokinetics: Following oral administration, the bioavailability of the drug is about 90% with 150 mg dose and 23-38% with higher doses.
An hour after a single dose of 150 mg oral clindamycin, plasma concentration reaches 2-3 mcg/mL. After 6 hours, it increases to an average of 0.7 mg/mL. Peak plasma concentrations are 4 mcg/mL for 300 mg dose and 8 mcg/mL for 600 mg dose.
Food reduces the rate of absorption of clindamycin but does not affect the extent of absorption of the drug.
Clindamycin is about 90% protein bound. Its half-life is 2-3 hours and is prolonged to 3.5 to 5 hours in patients with anuria, and to 7-14 hours in patients with liver disease. Half-life is also prolonged in preterm neonates.
Clindamycin is metabolized in the liver to its active metabolites, n-demethyl and sulfoxide metabolites and to some inactive ones.
The volume of distribution of clindamycin is 0.66 mL/g. It is distributed in most tissues, body fluids, and bone. Significant concentration of clindamycin enough to treat meningitis is not reached in the cerebrospinal fluid.
Clindamycin is eliminated in the liver and is slowly excreted as active drug and metabolites in the urine (10%) and in the feces (4%). Clindamycin cannot be removed by dialysis.
In patients with AIDS, clindamycin shows higher bioavailability. Plasma clearance and volume of distribution is lower.